1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. VBI Vaccines Inc.
  6. Company
    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
Real-time Estimate Cboe BZX  -  11:21 2022-08-10 am EDT
1.095 USD   +9.50%
08/08VBI VACCINES : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K
PU
08/08VBI VACCINES INC/BC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/08Earnings Flash (VBIV) VBI VACCINES Posts Q2 Revenue $346,000
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo VBI Vaccines Inc.
VBI Vaccines Inc. (VBI), is a biopharmaceutical company. VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is focused on targeting and overcoming infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). The Company’s products include 3-antigen HBV Vaccine Candidate; VBI-2900, which is a coronavirus vaccine program (VBI-2901, VBI-2902, VBI-2905); VBI-1501, which is prophylactic CMV vaccine candidate; VBI-2601, which is HBV Immunotherapeutic Candidate, and VBI-1901 GBM. The Company is conducting the Phase I/IIa clinical study of GBM vaccine immunotherapeutic candidate VBI-1901. It is also conducting the Phase I clinical study of prophylactic COVID-19 vaccine candidate, VBI-2902 and clinical study with VBI-2905, COVID-19 vaccine candidate against the Beta variant.
Sales per Business
20202021Delta
Research & Development Service0.7873.3%0.3758.5% -52.57%
Vaccines0.2826.7%0.2641.5% -7.42%
USD in Million
Sales per region
20202021Delta
Israel0.2826.8%0.3250.9% +13.03%
China/Hong Kong0.7268.2%0.3148.5% -57.73%
Europe0.055%0.000.6% -92.45%
USD in Million
Managers
Name Title Age Since
Jeff Baxter President, Chief Executive Officer & Director 59 2016
Christopher McNulty CFO, Director & Head-Business Development 44 2019
David Evander Anderson, Dr. Chief Scientific Officer 51 2016
Francisco Diaz-Mitoma, Dr. Chief Medical Officer 66 2016
Nicole Anderson Director-Corporate Communications & IR - 2019
Nell Beattie Chief Business Officer 33 2017
Avi Mazaltov Global Head-Manufacturing 59 2017
Misha Nossov Senior Vice President-Market Access & Commercial - -
Athena Kartsaklis Senior Vice President-Finance 56 -
T. Adam Buckley Vice President-Business Development 45 2001
Members of the board
Name Title Age Since
Steven H. Gillis, Dr. Chairman 68 2016
Michel de Wilde, Dr. Independent Director 71 2016
Blaine H. McKee, Dr. Independent Director 56 2019
Joanne Cordeiro Independent Director 63 2019
Damian Braga Independent Director 65 2020
Linda C. Bain Independent Director 50 2021
Jeff Baxter President, Chief Executive Officer & Director 59 2016
Christopher McNulty CFO, Director & Head-Business Development 44 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 258,257,494 204,573,369 79.2% 0 0.0% 79.2%
Shareholders
NameEquities%
Perceptive Advisors LLC 52,334,993 20.3%
ARCH Venture Partners LLC 13,026,057 5.04%
SSgA Funds Management, Inc. 12,372,113 4.79%
Viking Global Investors LP 8,798,971 3.41%
BlackRock Fund Advisors 5,291,150 2.05%
Menora Mivtachim Insurance Ltd. 5,259,868 2.04%
BVF Partners LP 4,722,572 1.83%
The Vanguard Group, Inc. 4,623,541 1.79%
Geode Capital Management LLC 3,929,576 1.52%
Cambridge Investment Research Advisors, Inc. 2,233,150 0.86%
Brand Portfolio
In partnership withAllbrands.markets
More brands of VBI Vaccines Inc.